Radiolabelled RGD Peptides for Imaging and Therapy

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2012 Mar 6

PMID 22388629

Citations 93

Authors

F C Gaertner

H Kessler

H-J Wester

M Schwaiger

A J Beer

Affiliations

Soon will be listed here.

Abstract

Imaging of angiogenesis has become increasingly important with the rising use of targeted antiangiogenic therapies like bevacizumab (Avastin). Non-invasive assessment of angiogenic activity is in this respect interesting, e.g. for response assessment of such targeted antiangiogenic therapies. One promising approach of angiogenesis imaging is imaging of specific molecular markers of the angiogenic cascade like the integrin α(v)β(3). For molecular imaging of integrin expression, the use of radiolabelled peptides is still the only approach that has been successfully translated into the clinic. In this review we will summarize the current data on imaging of α(v)β(3) expression using radiolabelled RGD peptides with a focus on tracers already in clinical use. A perspective will be presented on the future clinical use of radiolabelled RGD peptides including an outlook on potential applications for radionuclide therapy.

Citing Articles

EGFR- and Integrin αβ-Targeting Peptides as Potential Radiometal-Labeled Radiopharmaceuticals for Cancer Theranostics.

Rodrigues Toledo C, Tantawy A, Fuscaldi L, Malavolta L, de Aguiar Ferreira C Int J Mol Sci. 2024; 25(15).

PMID: 39126121 PMC: 11313252. DOI: 10.3390/ijms25158553.

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.

Javid H, Akbari Oryani M, Rezagholinejad N, Esparham A, Tajaldini M, Karimi-Shahri M Cancer Med. 2024; 13(2):e6800.

PMID: 38349028 PMC: 10832341. DOI: 10.1002/cam4.6800.

Theranostics with photodynamic therapy for personalized medicine: to see and to treat.

Wang Y, Staudinger J, Mindt T, Gasser G Theranostics. 2023; 13(15):5501-5544.

PMID: 37908729 PMC: 10614685. DOI: 10.7150/thno.87363.

Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.

Nhan N, Yamada T, Yamada K Int J Mol Sci. 2023; 24(16).

PMID: 37629112 PMC: 10454368. DOI: 10.3390/ijms241612931.

Cyclic Ruthenium-Peptide Conjugates as Integrin-Targeting Phototherapeutic Prodrugs for the Treatment of Brain Tumors.

Zhang L, Wang P, Zhou X, Bretin L, Zeng X, Husiev Y J Am Chem Soc. 2023; 145(27):14963-14980.

PMID: 37379365 PMC: 10347550. DOI: 10.1021/jacs.3c04855.

References

Chen X, Park R, Tohme M, Shahinian A, Bading J, Conti P . MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem. 2004; 15(1):41-9. DOI: 10.1021/bc0300403. View

Reardon D, Nabors L, Stupp R, Mikkelsen T . Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs. 2008; 17(8):1225-35. PMC: 2832832. DOI: 10.1517/13543784.17.8.1225. View

Cai W, Chen X . Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008; 49 Suppl 2:113S-28S. DOI: 10.2967/jnumed.107.045922. View

Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1(1):27-31. DOI: 10.1038/nm0195-27. View

Higashi K, Ito K, Hiramatsu Y, Ishikawa T, Sakuma T, Matsunari I . 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med. 2005; 46(2):267-73. View

Pichler B, Kneilling M, Haubner R, Braumuller H, Schwaiger M, Rocken M . Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. J Nucl Med. 2005; 46(1):184-9. View

Haubner R, Wester H, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman S . Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001; 42(2):326-36. View

Beer A, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik P . Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med. 2008; 49(2):255-9. DOI: 10.2967/jnumed.107.045526. View

Johnson J . Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev. 2000; 18(3):345-57. DOI: 10.1023/a:1006304806799. View

10.

Schnell O, Krebs B, Wagner E, Romagna A, Beer A, Grau S . Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 2008; 18(3):378-86. PMC: 2607528. DOI: 10.1111/j.1750-3639.2008.00137.x. View

11.

Huang B, Law M, Khong P . Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009; 251(1):166-74. DOI: 10.1148/radiol.2511081300. View

12.

Wu Z, Li Z, Cai W, He L, Chin F, Li F . 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2007; 34(11):1823-1831. PMC: 4167588. DOI: 10.1007/s00259-007-0427-0. View

13.

Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher D, Liu S . microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005; 46(10):1707-18. View

14.

Galbraith S . Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. Br J Radiol. 2004; 76 Spec No 1:S83-6. DOI: 10.1259/bjr/15255885. View

15.

Wu Z, Li Z, Chen K, Cai W, He L, Chin F . microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med. 2007; 48(9):1536-44. PMC: 4183663. DOI: 10.2967/jnumed.107.040816. View

16.

Jeswani T, Padhani A . Imaging tumour angiogenesis. Cancer Imaging. 2005; 5:131-8. PMC: 1665235. DOI: 10.1102/1470-7330.2005.0106. View

17.

Takada Y, Ye X, Simon S . The integrins. Genome Biol. 2007; 8(5):215. PMC: 1929136. DOI: 10.1186/gb-2007-8-5-215. View

18.

Beer A, Grosu A, Carlsen J, Kolk A, Sarbia M, Stangier I . [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007; 13(22 Pt 1):6610-6. DOI: 10.1158/1078-0432.CCR-07-0528. View

19.

Chatziioannou A . Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. Proc Am Thorac Soc. 2005; 2(6):533-6, 510-11. PMC: 2713341. DOI: 10.1513/pats.200508-079DS. View

20.

Haubner R, Kuhnast B, Mang C, Weber W, Kessler H, Wester H . [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004; 15(1):61-9. DOI: 10.1021/bc034170n. View